Show simple item record

dc.contributor.authorYeung, Jen_US
dc.contributor.authorEsposito, MTen_US
dc.contributor.authorGandillet, Aen_US
dc.contributor.authorZeisig, BBen_US
dc.contributor.authorGriessinger, Een_US
dc.contributor.authorBonnet, Den_US
dc.contributor.authorSo, CWEen_US
dc.identifier.citationCANCER CELL, 2010, 18 pp. 606 - 618en_US
dc.description.abstractIdentification of molecular pathways essential for cancer stem cells is critical for understanding the underlying biology and designing effective cancer therapeutics. Here, we demonstrated that beta-catenin was activated during development of MLL leukemic stem cells (LSCs). Suppression of beta-catenin reversed LSCs to a pre-LSC-like stage and significantly reduced the growth of human MLL leukemic cells. Conditional deletion of beta-catenin completely abolished the oncogenic potential of MLL-transformed cells. In addition, established MLL LSCs that have acquired resistance against GSK3 inhibitors could be resensitized by suppression of beta-catenin expression. These results unveil previously unrecognized multifaceted functions of beta-catenin in the establishment and drug-resistant properties of MLL stem cells, highlighting it as a potential therapeutic target for an important subset of AMLs.en_US
dc.format.extent606 - 618en_US
dc.publisherCELL PRESSen_US
dc.titlebeta-Catenin Mediates the Establishment and Drug Resistance of MLL Leukemic Stem Cellsen_US
dc.typeJournal Article
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfCANCER CELLen_US
pubs.notesaffiliation: So, CWE (Reprint Author), Kings Coll London, Dept Haematol Med, Leukaemia & Stem Cell Biol Grp, Denmark Hill, London SE5 9NU, England. Yeung, Jenny; Esposito, Maria Teresa; Zeisig, Bernd B.; So, Chi Wai Eric, Kings Coll London, Dept Haematol Med, Leukaemia & Stem Cell Biol Grp, London SE5 9NU, England. Gandillet, Arnaud; Griessinger, Emmanuel; Bonnet, Dominique, London Res Inst, Canc Res UK Haematopoiet Stem Cell Grp, London WC2A 3PX, England. So, Chi Wai Eric, Inst Canc Res, Haematooncol Sect, Sutton SM2 5NG, Surrey, England. keywords-plus: ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC PROGENITORS; CHILDHOOD LEUKEMIA; GAMMA-CATENIN; LONG-TERM; CANCER; MURINE; MAINTENANCE; MODEL; IDENTIFICATION research-areas: Oncology; Cell Biology web-of-science-categories: Oncology; Cell Biology author-email: researcherid-numbers: Griessinger, Emmanuel/G-5574-2018 funding-acknowledgement: CRUK; AICR; Kay Kendall Leukaemia Fund; [037632] funding-text: We thank M. Greaves and H. Gronemeyer for critical discussion; A. Wilson, A. Ford, L.-L. Smith, O. Yip, W. Vetharoy, A. Thornhill, C. Foley, I. Titley, G. Vijayaraghavan, P. Ernst, and D. Burgess for technical assistance and advice; A. Swain, M. Garrett, R. Fodde, P. Sonneveld, J. Veldscholte, R. Moon, D. Livingston, T. Reya, T.A. Hughes, and J. Sethi for useful reagents; King’s College Hospital and Anthony Nolan Cell Therapy Centre for provision of human cord blood; P. East for bioinformatics; S. Horswell for statistical analysis; and P. Tse for graphic assistance. Microarrays experiments were carried out at the Cancer Research UK (CRUK) Paterson Institute, Manchester, UK. D.B. is funded by CRUK and European grant (contract No:037632). C.W.E.S. is an Association for International Cancer Research (AICR) fellow and a European Molecular Biology Organization (EMBO) young investigator. This work is supported by the AICR, CRUK, and Kay Kendall Leukaemia Fund. number-of-cited-references: 48 times-cited: 135 usage-count-last-180-days: 1 usage-count-since-2013: 15 journal-iso: Cancer Cell doc-delivery-number: 697PL unique-id: ISI:000285527300011 oa: gold_or_bronze da: 2018-08-16en_US
pubs.notesNot knownen_US
pubs.embargo.termsNot knownen_US
dc.contributor.icrauthorSo, Chi Wai Ericen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record